Aurinia Pharmaceuticals Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Aurinia Pharmaceuticals Inc. (AUPH) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.84M, a 47.81% decline year-over-year.
- Aurinia Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was -$866.00K.
- Aurinia Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $5.92M, a 28.92% decline year-over-year.
- Aurinia Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $5.44M, a 36.64% decline year-over-year.
- Aurinia Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $14.68M, a 53.54% decline from fiscal 2024.
- Aurinia Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $31.60M, a 30.27% decline from fiscal 2023.
- Aurinia Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $45.31M, a 40.28% increase from fiscal 2022.
- Aurinia Pharmaceuticals Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $32.30M, a 3.38% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.84M 10-Q · filed 2026-08-06 | $1.97M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$866.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $14.68M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $5.92M 10-Q · filed 2025-11-04 | $11.36M derived: sum of 2 quarters · filed 2026-08-06 | $7.95M derived: sum of 3 quarters · filed 2026-08-06 | $16.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.44M 10-Q · filed 2026-08-06 | $2.03M derived: sum of 2 quarters · filed 2026-08-06 | $10.98M derived: sum of 3 quarters · filed 2026-08-06 | $19.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$3.41M 10-Q · filed 2026-08-06 | $5.54M derived: sum of 2 quarters · filed 2026-08-06 | $13.86M derived: sum of 3 quarters · filed 2026-08-06 | $22.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | $8.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $17.27M derived: sum of 2 quarters · filed 2026-02-26 | $25.86M derived: sum of 3 quarters · filed 2026-02-26 | $31.60M 10-K · filed 2026-02-26 |
| 2024-09-30 | $8.33M 10-Q · filed 2025-11-04 | $16.91M derived: sum of 2 quarters · filed 2025-11-04 | $22.65M 10-Q · filed 2024-11-07 | $34.42M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $8.59M 10-Q · filed 2025-11-04 | $14.32M 10-Q · filed 2024-08-01 | $26.09M derived: sum of 3 quarters · filed 2026-02-26 | $37.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $5.74M 10-Q · filed 2025-11-04 | $17.50M derived: sum of 2 quarters · filed 2026-02-26 | $29.31M derived: sum of 3 quarters · filed 2026-02-26 | $41.58M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $11.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $23.58M derived: sum of 2 quarters · filed 2026-02-26 | $35.84M derived: sum of 3 quarters · filed 2026-02-26 | $45.31M 10-K · filed 2026-02-26 |
| 2023-09-30 | $11.81M 10-Q · filed 2024-11-07 | $24.08M derived: sum of 2 quarters · filed 2024-11-07 | $33.54M 10-Q · filed 2024-11-07 | $40.45M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $12.27M 10-Q · filed 2024-08-01 | $21.73M 10-Q · filed 2024-08-01 | $28.64M derived: sum of 3 quarters · filed 2025-02-27 | $36.96M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $9.47M 10-Q · filed 2024-05-02 | $16.37M derived: sum of 2 quarters · filed 2025-02-27 | $24.69M derived: sum of 3 quarters · filed 2025-02-27 | $34.74M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $6.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $15.22M derived: sum of 2 quarters · filed 2025-02-27 | $25.28M derived: sum of 3 quarters · filed 2025-02-27 | $32.30M 10-K · filed 2025-02-27 |
| 2022-09-30 | $8.32M 10-Q · filed 2023-11-02 | $18.38M derived: sum of 2 quarters · filed 2023-11-02 | $25.40M 10-Q · filed 2023-11-02 | $33.98M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $10.05M 10-Q · filed 2023-08-03 | $17.08M 10-Q · filed 2023-08-03 | $25.66M derived: sum of 3 quarters · filed 2024-02-15 | $32.75M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $7.02M 10-Q · filed 2023-05-04 | $15.60M derived: sum of 2 quarters · filed 2024-02-15 | $22.69M derived: sum of 3 quarters · filed 2024-02-15 | $30.45M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $8.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $15.67M derived: sum of 2 quarters · filed 2024-02-15 | $23.42M derived: sum of 3 quarters · filed 2024-02-15 | $31.24M 10-K · filed 2024-02-15 |
| 2021-09-30 | $7.09M 10-Q · filed 2022-11-03 | $14.85M derived: sum of 2 quarters · filed 2022-11-03 | $22.67M 10-Q · filed 2022-11-03 | $27.81M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $7.75M 10-Q · filed 2022-08-04 | $15.57M 10-Q · filed 2022-08-04 | $20.72M derived: sum of 3 quarters · filed 2023-02-28 | $25.33M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $7.82M 10-Q · filed 2022-05-10 | $12.97M derived: sum of 2 quarters · filed 2023-02-28 | $17.58M derived: sum of 3 quarters · filed 2023-02-28 | $21.78M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $5.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $9.76M derived: sum of 2 quarters · filed 2023-02-28 | $13.96M derived: sum of 3 quarters · filed 2023-02-28 | $17.45M 10-K · filed 2023-02-28 |
| 2020-09-30 | $4.61M 10-Q · filed 2021-11-03 | $8.81M derived: sum of 2 quarters · filed 2021-11-03 | $12.31M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $4.20M 10-Q · filed 2021-08-05 | $7.70M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $3.50M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $7.41M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $6.86M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |